The anti-tumor necrosis factor agent, infliximab, may increase the risk of peri-operative complications.
In this study, physicians from Belgium evaluated a cohort of 313 Crohn's disease patients treated with infliximab. Of these patients, 40 received ≥ 1 infliximab infusions prior to intestinal resection.
|The length of hospital stay after surgery was similar between the 2 groups.|
|Alimentary Pharmacology and Therapeutics|
The team compared any post-operative events in these patients with those in an infliximab naÔve control group. Early (10 days) and late (3 months) major or minor complications were identified.
The physicians found that the incidence of early minor and major complications, and late minor and major complications were similar between the groups. The mean hospital stay after surgery was also similar.
The team identified a trend towards an increased early infection rate in infliximab treated patients, but more patients in this group received corticosteroids and/or immunosuppressives.
Dr Marchal and colleagues concluded, "The use of infliximab before intestinal resection does not prolong the hospital stay and does not increase the rate of post-operative complications".